⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RIGL News
Rigel Pharmaceuticals Inc. (New)
Form 8-K
sec.gov
RIGL
Rigel Reports First Quarter 2026 Financial Results
prnewswire.com
RIGL
Form 8-K
sec.gov
RIGL
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com
RIGL
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
prnewswire.com
RIGL
Form 8-K
sec.gov
RIGL
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
prnewswire.com
RIGL
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
globenewswire.com
FHTX
CRNX
RIGL
Rigel Appoints Michael P. Miller to the Board of Directors
prnewswire.com
RIGL
Zapata Secures Foundational Patent for Interoperable Quantum Software Across Key Global Markets
globenewswire.com
MSFT
NVDA
RIGL